QualitecFarma starts clinical operations from its headquarters in USA
The company is dedicated to providing international support to the pharmaceutical and biotechnology industry in the development of its products
Qualitecfarma is a company dedicated to providing international support to the pharmaceutical and biotechnology industry in the development of its products, as well as helping companies in the biomedical area to establish operations in the EU for more than 20 years.
Aware of the high level acquired by the Spanish biotechnology sector and that it is playing an increasingly important role within the country's economy, QualitecFarma has opened an access point in the United States to the experience acquired, which will contribute to the transfer of knowledge and the company's own expansion in that country. Specifically, in 2019, QualitecFarma Research & Clinical Strategies establishes a corporate headquarters there, consolidating its expansion in the United States.
The business background over more than 20 years of this CRO, of purely Spanish capital, has resulted in the beginning of operations in the field of clinical research in North America. While it is true that Qualitecfarma has been working for many years with American companies in the pharmaceutical industry, supporting them in the establishment and development of operations in Spain and the rest of Europe, it was in 2019 when it became involved in the development of its first clinical trial in the USA, specifically in the area of paediatric oncology with a product of Spanish invention and development, in different high-level centres such as Dana Farber in Boston and Hackensack in New York.
QualitecFarma expects a significant growth of its operational capacity with this expansion plan, which will include, over the next few years, the development of bidirectional business between America and Europe in the top of biopharmaceutical innovation.
This ambitious expansion plan consolidates the company's operations development project for the coming years, which is also backgrounded and supported by a strong commitment and investment in quality systems and technology for the development of the activity at the highest level.